Personalised medicine – lower costs

A recent Vlerick MBA in-company project has resulted in discussions at policy level in the UK. The research, carried out in conjunction with Science|Business, a think tank that connects industry, policy and research across Europe, evaluated the financial and cost-effectiveness impacts of investing in new IT and diagnostic technologies for personalised healthcare in the UK. The conclusions reveal that such investments really do pay off. Not only do patients benefit, but long-term costs can also be dramatically reduced by better screening of patients and easier access to treatment and medication, particularly in the case of breast cancer and cardiovascular disease, two of the most common health conditions today. This opens the door for new and innovative initiatives from the business world.

Previous Overview Next